ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q3 2021
The revenue in September for Zinzino's sales markets increased by 10% to SEK 111.6 (101.7) million due to solid growth in several regions. Faun Pharma's external sales increased by 13% and amounted to SEK 6.2 (5.5) million. Overall, the Group increased revenues by 10% to SEK 117.8 (107.2) million compared with the previous year.
The third quarter of 2021 became a solid quarter; the Zinzino based revenue in July – September increased by 11% to SEK 298.8 (269.0) million compared with previous year. Total group revenue increased by 11% to SEK 312.9 (281.8) million.
Accumulated revenue for January – September 2021 increased by 21% to SEK 968.7 (798.2) million.
Revenues were distributed as follows:
| Regions,MSEK | 21-Sep | 20-Sep | Change | Q3 2021 | Q3 2020 | Change | YTD 2021 | YTD 2020 | Change |
| The Nordics | 29.4 | 34.3 | -14% | 85.0 | 95.7 | -11% | 271.8 | 287.5 | -5% |
| Central Europe | 20.6 | 16.7 | 23% | 55.4 | 47.1 | 18% | 163.3 | 125.9 | 30% |
| East Europe | 29.6 | 24.3 | 22% | 78.9 | 64.3 | 23% | 239.3 | 187.4 | 28% |
| South & West Europe | 12.3 | 9.5 | 29% | 32.9 | 25.4 | 30% | 103.4 | 57.2 | 81% |
| The Baltics | 6.4 | 5.5 | 16% | 16.9 | 15.4 | 10% | 52.5 | 48.8 | 8% |
| North America | 4.6 | 4.4 | 5% | 11.4 | 11.6 | -2% | 36.5 | 29.8 | 22% |
| Asia-Pacific | 8.7 | 7.0 | 24% | 18.3 | 9.5 | 93% | 54.5 | 19.4 | 181% |
| Zinzino | 111.6 | 101.7 | 10% | 298.8 | 269.0 | 11% | 921.3 | 756.0 | 22% |
| Faun Pharma | 6.2 | 5.5 | 13% | 14.1 | 12.8 | 10% | 47.4 | 42.2 | 12% |
| Zinzino Group | 117.8 | 107.2 | 10% | 312.9 | 281.8 | 11% | 968.7 | 798.2 | 21% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, Malaysia, Singapore, Taiwan, Thailand
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 15:30 the 5th of October 2021.
Zinzino is a global D2C company from Scandinavia specializing in biomarker-based, personalized nutrition. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their test-based, scientifically proven nutritional supplements are available in close to 100 markets across the world.
Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia, India and Taiwan.
Tags:
